Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessment of activity levels for CYP2D61, CYP2D62, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan.

Clinical pharmacology and therapeutics - 1 Nov 2010

Abduljalil K, Frank D, Gaedigk A, Klaassen T, Tomalik-Scharte D, Jetter A, Jaehde U, Kirchheiner J, Fuhr U

Abstract excerpt

The pharmacokinetics of dextromethorphan (DM) is markedly influenced by cytochrome P450 2D6 (CYP2D6) enzyme polymorphisms. The aim of this study was to quantify the effects of the CYP2D6*1, *2, and *41 variants on DM metabolism in vivo and to identify other sources of pharmacokinetic variability. Concentrations of DM and dextrorphan (DO) in plasma and urine were evaluated in 36 healthy Caucasian men. These...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Biotransformation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Cytochrome P-450 CYP2D6

Share to Dextromethorphan

Share to Hydrogen-Ion Concentration

Share to Models, Biological

Share to White People

Source

Identifiers

PMID: 20881950
DOI: 10.1038/clpt.2010.137

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan.PMID 20881950Read ↗

Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphanSemantic proximity Read ↗

Evaluation of cytochrome P450 2D6 phenotyping in healthy adult Western Indians.Semantic proximity Read ↗

Inter-individual variability of in vivo CYP2D6 activity in different genotypes.Semantic proximity Read ↗

Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes.Semantic proximity Read ↗

CYP2D6 genotype and phenotype relationship in South Indians.Semantic proximity Read ↗

Cytochrome P450 2D6 polymorphism in eastern Indian population.Semantic proximity Read ↗

Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.Semantic proximity Read ↗

Genetic polymorphism of CYP2D6 in North Indian subjects.Semantic proximity Read ↗

Discovery of novel functional variants and extensive evaluation of CYP2D6 genetic polymorphisms in Koreans.Semantic proximity Read ↗

CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication.Semantic proximity Read ↗

CYP2D6 phenotyping with dextromethorphan.Semantic proximity Read ↗

Frequency distribution of dextromethorphan O-demethylation in a Greek population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.